CA
VRTX icon

CV Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

CV Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
+3,200
New +$1.42M 0.29% 39

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

CV Advisors's VRTX Position: Q2 2026 in Review

CV Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 3,200 shares worth $1.59M. The stake represents 0.29% of the portfolio and ranks #39 among its holdings.

354 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • CV Advisors held 3,200 shares of Vertex Pharmaceuticals worth $1.59M as of Q2 2026.
  • Vertex Pharmaceuticals was a new CV Advisors position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.29% of CV Advisors's portfolio in Q2 2026, its #39 holding.
  • 354 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on CV Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.